To include your compound in the COVID-19 Resource Center, submit it here.

Sage's SAGE-217 meets in Phase I/II using model of insomnia

Sage Therapeutics Inc. (NASDAQ:SAGE) reported top-line data from a double-blind, crossover, U.S. Phase I/II trial in 45 healthy volunteers showing that single doses of 30 and

Read the full 267 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE